WO2003016266A1 - β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF - Google Patents
β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF Download PDFInfo
- Publication number
- WO2003016266A1 WO2003016266A1 PCT/JP2002/008211 JP0208211W WO03016266A1 WO 2003016266 A1 WO2003016266 A1 WO 2003016266A1 JP 0208211 W JP0208211 W JP 0208211W WO 03016266 A1 WO03016266 A1 WO 03016266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- hiv agents
- hiv
- inhibitory activity
- integrase
- Prior art date
Links
- -1 β-KETOAMIDE COMPOUNDS Chemical class 0.000 title abstract 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 abstract 4
- 229940124411 anti-hiv antiviral agent Drugs 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 108010002459 HIV Integrase Proteins 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108010061833 Integrases Proteins 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-247346 | 2001-08-16 | ||
| JP2001247346 | 2001-08-16 | ||
| JP2001372066 | 2001-12-05 | ||
| JP2001-372066 | 2001-12-05 | ||
| JP2002-151232 | 2002-05-24 | ||
| JP2002151232 | 2002-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003016266A1 true WO2003016266A1 (en) | 2003-02-27 |
Family
ID=27347336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2002/008211 WO2003016266A1 (en) | 2001-08-16 | 2002-08-12 | β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF |
Country Status (2)
| Country | Link |
|---|---|
| PE (1) | PE20030434A1 (ja) |
| WO (1) | WO2003016266A1 (ja) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006520759A (ja) * | 2003-03-21 | 2006-09-14 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたｐ−ジアミノベンゼン誘導体 |
| US7109186B2 (en) | 2002-07-09 | 2006-09-19 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7211572B2 (en) | 2003-08-13 | 2007-05-01 | Japan Tobacco Inc. | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| US7820818B2 (en) | 2002-08-30 | 2010-10-26 | Novartis Ag | Heteroaryl nitrile derivatives |
| US8609717B2 (en) | 2010-08-18 | 2013-12-17 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators |
| US9533976B2 (en) | 2013-02-22 | 2017-01-03 | Samumed, Llc | γ-diketones as WNT/β-catenin signaling pathway activators |
| US9795550B2 (en) | 2014-08-20 | 2017-10-24 | Samumed, Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| EP2344456B1 (en) * | 2008-08-29 | 2018-07-25 | Japan Tobacco Inc. | Novel potassium channel blocker |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07267903A (ja) * | 1994-03-31 | 1995-10-17 | Nagase & Co Ltd | 抗ｈｉｖ活性を有するフッ素含有化合物 |
| WO1999062520A1 (en) * | 1998-06-03 | 1999-12-09 | Merck & Co., Inc. | Hiv integrase inhibitors |
| WO2001096283A2 (en) * | 2000-06-16 | 2001-12-20 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
-
2002
- 2002-08-12 WO PCT/JP2002/008211 patent/WO2003016266A1/ja active Application Filing
- 2002-08-15 PE PE2002000740A patent/PE20030434A1/es not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07267903A (ja) * | 1994-03-31 | 1995-10-17 | Nagase & Co Ltd | 抗ｈｉｖ活性を有するフッ素含有化合物 |
| WO1999062520A1 (en) * | 1998-06-03 | 1999-12-09 | Merck & Co., Inc. | Hiv integrase inhibitors |
| WO2001096283A2 (en) * | 2000-06-16 | 2001-12-20 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109186B2 (en) | 2002-07-09 | 2006-09-19 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7820818B2 (en) | 2002-08-30 | 2010-10-26 | Novartis Ag | Heteroaryl nitrile derivatives |
| JP2006520759A (ja) * | 2003-03-21 | 2006-09-14 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたｐ−ジアミノベンゼン誘導体 |
| US7906537B2 (en) | 2003-03-21 | 2011-03-15 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
| US7211572B2 (en) | 2003-08-13 | 2007-05-01 | Japan Tobacco Inc. | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| EP2042502A1 (en) | 2003-08-13 | 2009-04-01 | Japan Tobacco Inc. | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| EP2344456B1 (en) * | 2008-08-29 | 2018-07-25 | Japan Tobacco Inc. | Novel potassium channel blocker |
| US8609717B2 (en) | 2010-08-18 | 2013-12-17 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators |
| US8921413B2 (en) | 2010-08-18 | 2014-12-30 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators |
| US9303010B2 (en) | 2010-08-18 | 2016-04-05 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators |
| US9493437B2 (en) | 2010-08-18 | 2016-11-15 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as Wnt/ β-catenin signaling pathway activators |
| US8629176B1 (en) | 2010-08-18 | 2014-01-14 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators |
| US10314832B2 (en) | 2010-08-18 | 2019-06-11 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators |
| US9884053B2 (en) | 2010-08-18 | 2018-02-06 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators |
| US9533976B2 (en) | 2013-02-22 | 2017-01-03 | Samumed, Llc | γ-diketones as WNT/β-catenin signaling pathway activators |
| US9951053B2 (en) | 2013-02-22 | 2018-04-24 | Samumed, Llc | γ-diketones as Wnt/β-catenin signaling pathway activators |
| US10457672B2 (en) | 2013-02-22 | 2019-10-29 | Samumed, Llc | γ-diketones as Wnt/β-catenin signaling pathway activators |
| US11034682B2 (en) | 2013-02-22 | 2021-06-15 | Samumed, Llc | Gamma-diketones as wnt/β-catenin signaling pathway activators |
| US11673885B2 (en) | 2013-02-22 | 2023-06-13 | Biosplice Therapeutics, Inc. | γ-diketones as Wnt/β-catenin signaling pathway activators |
| US9795550B2 (en) | 2014-08-20 | 2017-10-24 | Samumed, Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| US10434052B2 (en) | 2014-08-20 | 2019-10-08 | Samumed, Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| US11077046B2 (en) | 2014-08-20 | 2021-08-03 | Biosplice Therapeutics, Inc. | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| US11839679B2 (en) | 2014-08-20 | 2023-12-12 | Biosplice Therapeutics, Inc. | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20030434A1 (es) | 2003-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1564210A4 (en) | 4-OXOCHINOLINE COMPOUNDS AND THEIR USE AS HIV INTEGRASE INHIBITORS | |
| TW200510425A (en) | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | |
| EP2033954A4 (en) | COMPOUND 6- (4-OXOQUINOLIN-SUBSTITUTED BENZYL) AND USE THEREOF AS INHIBITOR OF HIV INTEGRASE | |
| AU2003292437A1 (en) | Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors | |
| EA200601654A1 (ru) | Ингибиторы интегразы вич | |
| DK1441734T3 (da) | Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase | |
| DE69637976D1 (de) | Verwendung von Ritonavir (abt-538) zur Verbesserung der Pharmakokinetik von Arzneimitteln, die durch Cytochrom p450 metabolisiert werden, im Rahmen einer Behandlung von AIDS | |
| CA2463976A1 (en) | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | |
| CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| IN2012DN06436A (ja) | ||
| WO2003016266A1 (en) | β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | |
| WO2002000166A3 (en) | New compounds useful as antibacterial agents | |
| CA2417935A1 (en) | Anti-inflammatory medicament | |
| CA2504872A1 (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
| WO2006044968A3 (en) | Combination therapy for treating viral infections | |
| EA199700150A1 (ru) | КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC | |
| WO2004047725A3 (en) | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | |
| WO2002009717A1 (fr) | Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif | |
| AU2001267561A1 (en) | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents | |
| WO2003024941A1 (fr) | Composes de naphtalene et leur utilisation comme medicament | |
| EP1411956B8 (en) | Use of oversulfated polysaccharides as inhibitors of hiv | |
| WO2005115147A3 (en) | Hiv reverse transcriptase inhibitors | |
| WO2001070216A3 (en) | Diphenyl ketoaldehyde derivatives with anti-hiv activity | |
| WO1996041634A3 (en) | Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection | |
| CA2499620A1 (en) | External preparation containing acetylsalicylic acid for inhibiting keloid formation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS KE KG KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |